NRSN — Neurosense Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Neurosense Reports New Data on Clinical Efficacy In Phase 2b ALS Trial
Brief: NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Neurosense Therapeutics Ltd expected to post a loss of 24 cents a share - Earnings Preview
Brief: Neurosense Receives U.S. FDA Confirmation Of CMC Strategy For Primec
Brief: NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial
Brief: Neurosense Says Phase 2 Alzheimer's Study Expected To Enroll First Patient In Next Several Weeks
Brief: Neurosense's Primec Demonstrates Outstanding Effect On ALS Survival In Innovative IPSC Model
Brief: Neurosense Ends Its At-The-Market Equity Offering Program
Brief: Neurosense Therapeutics Ltd Got Notice From Nasdaq That Co No Longer Meets Minimum Bid Price Requirement For Continued Listing
Brief: European Medicines Agency Grants Neurosense Sme Status
Brief: Neurosense Therapeutics says Granted Patents In Europe, Japan, And Israel For Its Als Drug Primec
Neurosense Therapeutics Ltd expected to post a loss of 28 cents a share - Earnings Preview
Neurosense Therapeutics Ltd expected to post a loss of 28 cents a share - Earnings Preview
Neurosense Therapeutics Ltd expected to post a loss of 28 cents a share - Earnings Preview
Neurosense Therapeutics Ltd expected to post a loss of 28 cents a share - Earnings Preview
Brief: Neurosense CEO Provides Q2 2023 Update
Brief: NeuroSense Announces Pricing Of $4.5 Mln Registered Direct Offering And Concurrent Private Placement
Brief: Neurosense Reports First Quarter 2023 Financial Results & Provides Business Update Phase 2B Als Trial Completes Enrollment, Topline Data Expected Q4 2023
Brief: Neurosense Completes Enrollment In Phase 2B Als Clinical Trial